[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588110":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":16,"armGroups":11,"interventions":11,"overallOfficials":11,"centralContacts":17,"locations":23,"responsibleParty":42,"collaborators":11,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":11,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":11,"enrollmentInfo":55,"targetDuration":58,"studyType":59,"phases":11,"briefSummary":60,"conditions":61,"keywords":11,"overallStatus":25,"whyStopped":11,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Toho University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"the 1-year composite endpoint of all-cause death and major cardiac adverse events (MACE) including VHD intervention.",null,"one year",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":14,"timePerspective":15,"maskingInfo":11},"COHORT","PROSPECTIVE","The study will be conducted at 7 centers throughout Japan, with the goal of enrolling a total of approximately 300-350 cases.",[18],{"name":19,"role":20,"phone":21,"phoneExt":11,"email":22},"Hideki Koike, MD, PhD","CONTACT","81+3-3762-4151","hideki.koike@med.toho-u.ac.jp",[24],{"facility":5,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Ōta-ku","Tokyo","143-8540","Japan","JP",{"type":32,"coordinates":33},"Point",[34,35],139.71605,35.56126,{"lat":35,"lon":34},[38],{"name":39,"role":20,"phone":40,"phoneExt":11,"email":41},"Ethics Committee of the Toho University","81+3-5763-6534","omori.rinri@ext.toho-u.ac.jp",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Hideki Koike","Principal Investigator","100588110","evaluation-of-valvular-heart-disease-using-cardiac-ct-100588110",false,"NCT06937125","Evaluation of Valvular Heart Disease Using Cardiac CT","Evaluation of Valvular Heart Disease: Multicenter Registry of Noninvasive Imaging Modalities by Cardiac CT","Inclusion Criteria:\n\n* Patients with at least moderate valvular heart disease who had a cardiac CT with 64 or more rows\n* 18 years of age or older\n\nExclusion Criteria:\n\n* Less than 18 years old\n* Acute VHD\n* Infectious endocarditis\n* Patients with post-VHD intervention\n* Poor CT image quality for analyzing CT data.","ALL","18 Years",{"count":56,"type":57},350,"ESTIMATED","1 Year","OBSERVATIONAL","The EVIDENTIA Registry is a multicenter study designed to evaluate valvular heart disease (VHD) using cardiac CT. It aims to assess cardiac valve anatomy, function, and myocardial characteristics through detailed CT analysis.\n\n1. Assessing the accuracy of cardiac CT in evaluating cardiac structure, volume, function, and myocardium in VHD patients.\n2. Comparing the severity, classification, and etiology (primary vs. functional) of VHD.\n3. Monitoring serial changes in VHD severity via echocardiography.\n4. Investigating the relationship between echocardiographic and CT-derived parameters.\n5. Examining the correlation between imaging findings, VHD interventions, and patient prognosis.",[62],"Valvular Heart Disease","2026-10-08",{"date":65,"type":66},"2026-10-09","ACTUAL",{"date":68,"type":66},"2025-03-12",{"date":70,"type":57},"2028-03",{"name":5,"class":6},1]